177960-62-2

Usage

Uses

Used in Pharmaceutical Synthesis:
Benzoic acid, 2-amino-5-fluoro-3-nitro(9CI) is used as an intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Synthesis:
Benzoic acid, 2-amino-5-fluoro-3-nitro(9CI) is also utilized in the production of agrochemicals, contributing to the development of effective pesticides and other agricultural products.
Used in Antimicrobial Applications:
Benzoic acid, 2-amino-5-fluoro-3-nitro(9CI) has been studied for its potential antimicrobial properties, making it a candidate for use in applications that require the inhibition of microbial growth.
Used in Antitumor Applications:
Due to its potential antitumor properties, Benzoic acid, 2-amino-5-fluoro-3-nitro- (9CI) is being investigated for use in cancer research and the development of novel anticancer agents.
Used in Chemical Research:
Benzoic acid, 2-amino-5-fluoro-3-nitro(9CI) serves as a subject of study in chemical research, where its properties and reactions are explored to further understand its potential applications and effects.

Upstream product

• 1266115-00-7 5-fluoro-3-nitro-2-(2,2,2-trifluoro acetamido)benzoic acid 
• 954571-39-2 5-fluoro-7-nitroindoline-2,3-dione 
• 446-08-2 2-amino-5-fluorobenzoic acid 
• 49579-59-1 5-fluoro-2-(2,2,2-trifluoroacetamido)benzoic acid 

Relevant academic research and scientific papers

Pyrimidine and imidazole compound, its pharmaceutical composition and its preparation and use

The invention relates to a pyrimidoimidazole derivative, a preparation method and medical use thereof, and particularly relates to a new pyrimidoimidazole derivative as shown in a general formula (I) or formula (II), a preparation method thereof, a pharma

BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PREPARATION METHOD AND USE THEREOF

The present invention relates to a class of benzimidazole-2-piperazine heterocyclic derivatives, a preparation method and medical use thereof. Specifically, the present invention relates to a new benzimidazole-2-piperazine heterocyclic derivative of general Formula (I), a preparation method, a pharmaceutical composition containing the same, and use thereof as a therapeutic agent and especially as a poly(ADP-ribose)polymerase (PARP) inhibitor.

Benzimidazole-2-piperazine heterocyclic compound, its pharmaceutical composition and its preparation and use

The invention discloses benzimidazole-2-piperazine heterocyclic compounds as well as pharmaceutical compositions, preparation methods and applications of the benzimidazole-2-piperazine heterocyclic compounds, relating to a cyanopyrimidine compound, a preparation method thereof and an application of the cyanopyrimidine compound as a medicine. Concretely, the invention relates to a novel cyanopyrimidine compound as shown in the formula (19), a preparation method of the novel cyanopyrimidine compound, a pharmaceutical composition containing the cyanopyrimidine compound and an application of the cyanopyrimidine compound serving as a therapeutic agent and particularly serving as a poly-ADP-ribose polymerase (PARP) inhibitor.

Benzimidazole-2-piperazine compound, its pharmaceutical composition and its preparation and use

The invention relates to a benzimidazole-2-piperazine derivative and a preparing method and application of the benzimidazole-2-piperazine derivative in medicine, in particular to a novel benzimidazole-2-piperazine derivative shown in the general formula (I), a preparing method of the derivative, a pharmaceutical composition containing the derivative and application of the derivative serving as a therapeutic agent, especially serving as a poly (ADP-ribose) polymerase (PARP) inhibitor. In the general formula (I), R refers to hydrogen or halogen, G refers to carbonyl or methylene, m is 1-2, n is 1-3, and Q refers to hydrogen or C1-C4 alkyl. When X is methylene and Y is NR1 or methylene, X is NR1; R1 refers to hydrogen, C1-C6 alkyl, benzyl, COR2 or SO2R2; R2 refers to the following groups which are not substituted or groups substituted by 1-3 substituent groups, including C1-C6 alkyl, C3-C8 naphthenic base, phenyl, benzyl, naphthyl and C5-C10 aromatic heterocycle base, heterocycle in the C5-C10 aromatic heterocycle base comprises 1-3 heteroatoms selected from N, O and S, and the substituent groups are selected from the following atoms or groups of C1-C6 alkyl, C1-C6 alkoxy, halogen, amidogen, nitryl, sulfydryl, hydroxyl, cyanogroup and trifluoromethyl. The general formula (I) is shown in the specification.

BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD AND USE THEREOF

The present invention relates to a class of benzimidazole-2-piperazine heterocyclic derivatives, a preparation method and medical use thereof. Specifically, the present invention relates to a new benzimidazole-2-piperazine heterocyclic derivative of general Formula (I), a preparation method, a pharmaceutical composition containing the same, and use thereof as a therapeutic agent and especially as a poly(ADP-ribose)polymerase (PARP) inhibitor.

2,5-diazabicyclo [2.2.1] iieptanes and method of preparation, pharmaceutical compositions thereof and its application in medicine

The present invention relates to a class of 2,5-diazabicyclo[2.2.1]heptane derivatives and a preparation thereof, pharmaceutical compositions of the 2,5-diazabicyclo[2.2.1]heptane derivatives, and medical uses of the 2,5-diazabicyclo[2.2.1]heptane derivat

OXADIAZOLE DERIVATIVES AND PHARMACEUTICAL USES THEREOF

PROBLEM TO BE SOLVED: To provide therapeutic or preventive agents for various diseases or symptoms associated with a serotonin 4 receptor (particularly, neuropsychiatric diseases such as Alzheimer-type dementia). SOLUTION: The present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. In the formula (1), Het represents formula (Het-1) or the like, A represents formula (A-1) or the like, B represents (B-1) or the like, R1A represents a hydrogen atom, an alkyl group or the like, R2A, R5, R6 and R7 represent a hydrogen atom, a halogen atom, an alkyl group or the like, R8 and R9 represent a hydrogen atom, an alkyl group or the like, and l represents an integer of 0-4. SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

DIHYDROOROTATE DEHYDROGENASE INHIBITORS

The invention relates to compounds of formula (I) wherein R1, R2, X1, X2, Y, Ra, Rb, Q have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.

BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS

Provided herein are sirtuin-modulating compounds of formula (II) The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Amino-benzoic acids and derivatives, and methods of use

The present invention relates to compounds, compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with a carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.